Risk Factors for Chemotherapy-Induced Peripheral Neuropathy Caused by Nanoparticle Albumin-Bound Paclitaxel in Advanced Breast Cancer

Table 1

Clinicopathological features of BC patients.

Clinical features	Number	Percentage (%)
Age
<55	52	57.7
≥55	38	42.2
BMI
<24.9	56	62.2
≥25	34	37.7
BSA
≤1.6	13	14.4
>1.6	77	85.5
Pathological type
IDC	57	63.3
Others	33	36.6
Clonal subpopulations
HER2+	10	11.1
TNBC	34	37.8
Luminal A	6	6.7
Luminal B (HER2-)	34	37.8
Luminal B (HER2+)	6	6.7
ECOG score
0	9	10
1	68	74.4
2	14	15.5
Usage and dosage
200 mg QW	62	68.8
400 mg Q3W	28	31.1
Chemotherapy cycles
≤4 cycles	37	41.1
>4 cycles	53	58.8
Chemotherapy regimens
Single	36	40
Combination	54	60
Metastatic lesions
1~2	44	48.8
≥3	46	51.1
Previous diseases
Diabetes	9	10
Hypertension	15	16.6
Others	12	13.3

BMI: body mass index; BSA: body surface area; ECOG: Eastern Cooperative Oncology Group.